Understanding the Evolving Landscape of Malignant Melanoma

Publication
Article
Pharmacy TimesMay 2017 Skin & Eye Health
Volume 83
Issue 5

This Continuing Education activity is supported by an educational grant from Merck Sharpe & Dohme Corp.

This activity is supported by an educational grant from Merck Sharpe & Dohme Corp.

Understanding the Evolving Landscape of Malignant Melanoma

Faculty

Cindy L. O’Bryant, PharmD, BCOP, FCCP, FHOPAProfessorUniversity of Colorado Skaggs School of Pharmacy and Pharmaceutical SciencesDepartment of Clinical PharmacyUniversity of Colorado Anschutz Medical CampusAshley E. Glode, PharmD, BCOPAssistant ProfessorUniversity of Colorado Skaggs School of Pharmacy and Pharmaceutical SciencesDepartment of Clinical PharmacyUniversity of Colorado Anschutz Medical CampusChristina M. Davis, PharmDPGY2 Oncology Pharmacy ResidentUniversity of Colorado Skaggs School of Pharmacy and Pharmaceutical SciencesUniversity of Colorado Anschutz Medical CampusJennifer E. MacDonald, PharmDPGY2 Oncology Pharmacy ResidentUniversity of Colorado Skaggs School of Pharmacy and Pharmaceutical SciencesUniversity of Colorado Anschutz Medical Campus

Educational Objectives

After completing this continuing education program, the participant will be able to:

  • Explore medical management of patients with malignant melanoma based on risk factors, presentation, assessment, and diagnosis parameters.
  • Discover current and emerging treatment options for malignant melanoma.
  • Employ the role of the pharmacist in supporting optimal treatment strategies in malignant melanoma management.

Target audience: Pharmacists, specialty pharmacists

Type of activity: Application

Release date: May 16, 2017

Expiration date: May 16, 2018

Estimated time to complete activity: 2.0 hours

Fee: Free

Pharmacy Times Continuing Education is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 2.0 contact hours (0.20 CEUs) under the ACPE universal activity number 0290-0000-17-047-H01-P. The activity is available for CE credit through May 16, 2018.

Related Videos
Practice Pearl #1 Active Surveillance vs Treatment in Patients with NETs
© 2024 MJH Life Sciences

All rights reserved.